These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6697335)

  • 1. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
    Conroy JF; Blessing JA; Kessinger A; Homesley HD
    Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ
    Cancer Treat Rep; 1981; 65(11-12):1127-9. PubMed ID: 7296557
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
    Slavik M; Arsenau JC; Blessing J; Lewis GC
    Am J Clin Oncol; 1982 Oct; 5(5):483-6. PubMed ID: 6897490
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
    Slavik M; Muss H; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Sep; 66(9):1775-7. PubMed ID: 6288239
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Ehrlich CE; Creasman WT; Curry S; Blessing JA
    Am J Clin Oncol; 1983 Jun; 6(3):273-5. PubMed ID: 6846245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
    Brubaker LH; Vogel CL; Einhorn LH; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):915-6. PubMed ID: 3087618
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I study of ICRF-187 using a daily for 3 days schedule.
    Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
    Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group.
    Thigpen JT; Lagasse L; Homesley H; Blessing JA
    Am J Clin Oncol; 1983 Aug; 6(4):431-5. PubMed ID: 6683465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 13. ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
    Conroy JF; Lewis GC; Blessing JA; Mangan C; Hatch K; Wilbanks G
    Am J Clin Oncol; 1984 Apr; 7(2):131-3. PubMed ID: 6702716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
    Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
    Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
    [No Abstract]   [Full Text] [Related]  

  • 16. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
    Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
    DeSimone PA; Greco FA; Omura GA; Bartolucci A
    Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.